Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE015 (POL) (Dr. Ito)
· consented 2022-07-29
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-08-22 (study day 12); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-21 (study day 133); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-03-12 (study day 214); relationship: N
moderate
assessed
2026-08-18
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-03-15 (study day 217); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-03 (study day 327); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.